C-reactive protein in outpatients with acute exacerbation of COPD: Its relationship with microbial etiology and severity

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2633-2640

  Gallego, Miguel ^a,b,c   Pomares, Xavier ^a,c   Capilla, Silvia ^d   Marcos, Maria Angeles ^e,f   Suárez, David ^b   Monsó, Eduard ^a,b,c   Montón, Concepción ^a,g  

^a HOSPITAL DE SABADELL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Institut Universitari Parc Tauli UAB   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g Health Services Research on Chronic Diseases Network REDISSEC   (Spain)

Author keywords

C reactive protein; COPD exacerbations; Hospital admission; Viruses

Indexed keywords

C REACTIVE PROTEIN; INFLUENZA VACCINE; OXYGEN; PNEUMOCOCCUS VACCINE; BIOLOGICAL MARKER;

ACUTE DISEASE; AGED; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; C REACTIVE PROTEIN BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYPERCAPNIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; OUTPATIENT; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PREDICTION; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RHINOVIRUS; RHINOVIRUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VIRUS IDENTIFICATION; BLOOD; DISEASE COURSE; HAEMOPHILUS INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, VIRAL; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPUTUM; STATISTICAL MODEL; UPREGULATION; VIROLOGY;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HAEMOPHILUS INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OUTPATIENTS; PATIENT ADMISSION; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, VIRAL; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPUTUM; UP-REGULATION;

EID: 85016084913     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S117129     Document Type: Article

References (35)

1. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11):925–931.
2. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
3. Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015; 21(3):278–283.
4. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–1645.
5. Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J. 2012;39(6):1354–1360.
6. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(9):1618–1623.
7. Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4): 896–904.
8. Miravitlles M, Moragas A, Hernández S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013;144(5):1571–1577.
9. Krüger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res. 2009;10(1):65.
10. Marin A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J. 2010;35(2):295–302.
11. Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76–86.
12. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874.
13. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.
14. Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14:103.
15. Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014;33(7):1101–1111.
16. Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.
18. From the global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2013. Available from: http://www.goldcopd.org/. Accessed January 7, 2016.
19. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011; 17(Suppl 6):E1–E59.
20. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J. 2004;23(6):932–946.
21. Hurst JR, Donaldson GC, Quint JK, Goldring JP, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5): 369–374.
22. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339–344.
23. Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of Clinical Microbiology. 5th Ed. Washington DC: American Society of Microbiology; 1991.
24. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J. 1997;10(5):1137–1144.
25. Coiras MT, Aguilar JC, García ML, Casas I, Pérez-Breña P. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J Med Virol. 2004;72(3):484–495.
26. Ko FW, Ip M, Chan PK, et al. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest. 2007;131(1):44–52.
27. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114–1121.
28. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219–225.
29. Peisajovich AL, Marnell C, Mold C, Du Clos TW. C reactive protein at the interface between innate immunity and inflammation. Exp Rev Clin Immunol. 2008;4(3):379–390.
30. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(3):269–278.
31. Ramírez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39(10):2211–2217.
32. Karadeniz G, Polat G, Senol G, Buyuksirin M. C-reactive protein measurements as a marker of the severity of chronic obstructive pulmonary disease exacerbations. Inflammation. 2013;36(4):948–953.
33. Postma DS, Burema J, Gimeno F, et al. Prognosis in severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1979;119(3): 357–367.
34. Quintana JM, Esteban C, Unzurrunzaga A, et al. Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments. BMC Med. 2014;12:66.
35. Vidal S, González N, Barrio I, et al. Predictors of hospital admission in exacerbations of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2013;17(12):1632–1637.